Sabril

GPTKB entity

Statements (59)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:approves gptkb:2009
gptkb:FDA
gptkbp:availability prescription only
gptkbp:brand gptkb:Sabril
gptkbp:category gptkb:C
gptkbp:class gptkb:Antihero
gptkbp:clinical_trial epilepsy treatment study
gptkbp:clinical_use long-term management of epilepsy
short-term treatment of infantile spasms
gptkbp:contraindication severe renal impairment
concurrent use of certain medications
hypersensitivity to vigabatrin
gptkbp:counseling_services importance of adherence to therapy
reporting any mood changes
risk of vision loss
gptkbp:dosage_form oral
gptkbp:formulation gptkb:tablet
powder for oral solution
https://www.w3.org/2000/01/rdf-schema#label Sabril
gptkbp:indication infantile spasms
gptkbp:ingredients vigabatrin
gptkbp:interacts_with gptkb:beer
other CNS depressants
other antiepileptic drugs
gptkbp:is_monitored_by gptkb:weight
kidney function
vision tests
gptkbp:manufacturer gptkb:Lundbeck
gptkbp:marketed_as gptkb:Sabril
gptkbp:mechanism_of_action inhibits GABA transaminase
gptkbp:packaging gptkb:bottle
blister pack
gptkbp:patient_population gptkb:children
adults
infants
gptkbp:pharmacokinetics excreted in urine
not extensively metabolized
half-life of 5 to 9 hours
gptkbp:research investigations into long-term effects
ongoing studies on efficacy in different populations
studies on combination therapy with other anticonvulsants
gptkbp:route_of_administration oral
gptkbp:safety not recommended for use in pregnancy unless necessary
monitoring required during treatment
risk of permanent vision loss
not recommended for use in breastfeeding without consulting a doctor
gptkbp:side_effect gptkb:depression
fatigue
irritability
drowsiness
weight gain
peripheral neuropathy
vision loss
somnolence
gptkbp:storage room temperature
gptkbp:used_for treating epilepsy
gptkbp:bfsParent gptkb:Lundbeck
gptkbp:bfsLayer 6